[New antibiotics in infection treatment].

التفاصيل البيبلوغرافية
العنوان:	[New antibiotics in infection treatment].
عنوان ترانسليتريتد:	Nowe antybiotyki w leczeniu zakażeń.
المؤلفون:	Płusa T; Medical Faculty of Łazarski University of Warsaw, Poland.
المصدر:	Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego [Pol Merkur Lekarski] 2018 Dec 28; Vol. 45 (270), pp. 213-219.
نوع المنشور:	Editorial
اللغة:	Polish
بيانات الدورية:	Publisher: Aluna Publishing Country of Publication: Poland NLM ID: 9705469 Publication Model: Print Cited Medium: Print ISSN: 1426-9686 (Print) Linking ISSN: 14269686 NLM ISO Abbreviation: Pol Merkur Lekarski Subsets: MEDLINE
أسماء مطبوعة:	Publication: 2023- : Konstancin-Jeziorna, Poland : Aluna Publishing Original Publication: Warszawa : MEDPRESS, [1996-
مواضيع طبية MeSH:	Anti-Bacterial Agents/therapeutic use , Infections/drug therapy, Microbial Sensitivity Tests
مستخلص:	The introduction of new molecules with antimicrobial activity is an opportunity for modern antibiotic therapy in the era of rapidly growing resistance to antibiotics. Beta-lactamase-inhibiting antibiotics, cephalosporinases and carbapenemases represent a breakthrough in previous treatments for infections caused by resistant pathogens. Ceftazidime with avibactam and ceftolozane with tazobactam show exceptional efficacy in severe infections. Karbavans is a combination of meropenem and a new boron beta-lactamase inhibitor, as well as the combination of avibactam and aztreonam, are a hope for the treatment of infections caused by Klebsiella pneumoniae resistant to the majority of available antibiotics. S649266 is itself an inhibitor of beta-lactamases. Plazomycin, in turn, is a new aminoglycoside that allows the control of severe bacterial infections caused by multiresistant Enterobacteriaceae, including those resistant to carbapenems. In contrast, omadacyclin, a semi-synthetic derivative of tetracycline, has activity against Gram-positive, Gram-negative, aerobic and anaerobic as well as atypical bacteria. Solithromycin, a new ketolide, has immunomodulatory effects and a broad antiinflammatory spectrum, with no side effects caused by older generations of macrolides. New fluoroquinolones (delafloxacin, zabofloxacin, finefloxacin, nemonoxacin, zoliflodacin) show a wide spectrum of action with less and less side effects. The new MRX-1 preapplate, alongside tedizolid and cadazolid, are further oxazolidinones that show significant activity against multi-resistant Gram-positive pathogens. The presented palette of new molecules with antimicrobial activity will certainly significantly improve the effectiveness of antibiotic therapy. (© 2018 MEDPRESS.)
فهرسة مساهمة:	Keywords: aminoglycosides; beta-lactamases; fluoroquinolones; ketolides; macrolides; oxazolidinones
المشرفين على المادة:	0 (Anti-Bacterial Agents)
تواريخ الأحداث:	Date Created: 20190130 Date Completed: 20190327 Latest Revision: 20191210
رمز التحديث:	20231215
PMID:	30693905
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	1426-9686